5VM
5AM Venture Management Portfolio holdings
AUM
$260M
This Quarter Return
-7.65%
1 Year Return
+3.76%
3 Year Return
+144.87%
5 Year Return
+32.61%
10 Year Return
–
AUM
$348M
AUM Growth
+$348M
(-13%)
Cap. Flow
+$4.85M
Cap. Flow
% of AUM
1.39%
Top 10 Holdings %
Top 10 Hldgs %
74.9%
Holding
26
New
2
Increased
2
Reduced
4
Closed
–
Top Buys
| 1 |
Dianthus Therapeutics
DNTH
|
$20.1M |
| 2 |
Tyra Biosciences
TYRA
|
$5.67M |
| 3 |
GH Research
GHRS
|
$2.54M |
| 4 |
Viridian Therapeutics
VRDN
|
$1.99M |
Top Sells
| 1 |
Crinetics Pharmaceuticals
CRNX
|
$11.9M |
| 2 |
Enliven Therapeutics
ELVN
|
$8.71M |
| 3 |
MoonLake Immunotherapeutics
MLTX
|
$2.52M |
| 4 |
Disc Medicine
IRON
|
$2.35M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Enliven Therapeutics
ELVN
$1.2B
| $70.5M | 20.29% |
5,160,975
-637,500
| -11% | -$8.71M |
|
2
Entrada Therapeutics
TRDA
$208M
| $69.7M | 20.04% |
4,408,379
| – | – |
|
|
3
Disc Medicine
IRON
$2.07B
| $20.6M | 5.93% |
438,442
-50,000
| -10% | -$2.35M |
|
|
4
Dianthus Therapeutics
DNTH
$759M
| $20.1M | 5.79% |
+1,472,264
| New | +$20.1M |
|
|
5
MoonLake Immunotherapeutics
MLTX
$3.54B
| $17.9M | 5.14% |
313,210
-44,276
| -12% | -$2.52M |
|
|
6
Crinetics Pharmaceuticals
CRNX
$2.92B
| $13.7M | 3.96% |
462,286
-400,000
| -46% | -$11.9M |
|
7
Vor Biopharma
VOR
$250M
| $13.5M | 3.88% |
6,361,723
| – | – |
|
8
Pharvaris
PHVS
$1.39B
| $12.3M | 3.53% |
587,600
| – | – |
|
9
Rallybio
RLYB
$22.4M
| $12.2M | 3.52% |
3,630,724
| – | – |
|
10
Zentalis Pharmaceuticals
ZNTL
$122M
| $9.83M | 2.83% |
490,000
| – | – |
|
11
scPharmaceuticals
SCPH
$295M
| $8.55M | 2.46% |
1,200,647
| – | – |
|
12
Celldex Therapeutics
CLDX
$1.47B
| $8.54M | 2.46% |
310,270
| – | – |
|
|
MRTX
13
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $8.39M | 2.41% |
192,500
| – | – |
|
14
Cogent Biosciences
COGT
$1.69B
| $7.71M | 2.22% |
790,440
| – | – |
|
15
Viking Therapeutics
VKTX
$3.04B
| $6.48M | 1.86% |
585,000
| – | – |
|
16
AnaptysBio
ANAB
$569M
| $6.42M | 1.85% |
357,733
| – | – |
|
|
17
Viridian Therapeutics
VRDN
$1.5B
| $6.29M | 1.81% |
410,000
+130,000
| +46% | +$1.99M |
|
18
Arvinas
ARVN
$568M
| $6.28M | 1.81% |
320,000
| – | – |
|
|
19
Tyra Biosciences
TYRA
$675M
| $5.67M | 1.63% |
+411,450
| New | +$5.67M |
|
|
SPRB
20
DELISTED
Spruce Biosciences, Inc. Common Stock
SPRB
| $5.34M | 1.54% |
2,364,000
| – | – |
|
21
Q32 Bio
QTTB
$20.9M
| $5.31M | 1.53% |
4,535,919
| – | – |
|
22
Avidity Biosciences
RNA
$5.99B
| $4.25M | 1.22% |
665,555
| – | – |
|
|
23
GH Research
GHRS
$837M
| $4.06M | 1.17% |
404,404
+252,382
| +166% | +$2.54M |
|
24
Mersana Therapeutics
MRSN
$36.5M
| $1.66M | 0.48% |
1,305,000
| – | – |
|
|
IMPL
25
DELISTED
Impel Pharmaceuticals Inc. Common Stock
IMPL
| $1.24M | 0.36% |
2,884,791
| – | – |
|